Not yet recruiting NCT07404111
A Study of VV-14305 for the Treatment of Thyroid Eye Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: VV-14305, Sham (No Treatment).
- Who it may be relevant to
- Registry conditions: Thyroid Eye Disease (TED). Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- New Zealand
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
An Adaptive Phase 1/2 MulticenteR Study Evaluating the Safety, Tolerability, Pharmacokinetics and EfficaCy of VV-14305 Delivered Via PeribuLbAr Injection in Patients With Moderate to Severe Thyroid Eye Disease (the RECLAIM Study)
Overview
The goal of this study is to evaluate the safety, tolerability, and efficacy of KRIYA-586 (VV-14305) in treating thyroid eye disease (TED).
Interventions
- Genetic VV-14305
VV-14305 will be administered via peribulbar injection. - Other Sham (No Treatment)
Sham solution such as Saline
Primary outcome measures
- Part 1: Safety and Tolerability of VV-14305 in participants with TED [Time frame: 52 Weeks]
- Part 2: Safety of VV-14305 in Participants with TED Compared to Sham [Time frame: 36 Weeks]
- Part 2: Efficacy of VV-14305 in participants with TED compared to Sham [Time frame: 36 Weeks]
Secondary outcome measures (8)
- Part 1: Efficacy associated with VV-14305 in participants with TED [Time frame: 52 Weeks]
- Efficacy associated with VV-14305 in participants with TED (as compared to Sham for Part 2) [Time frame: 52 Weeks]
- Efficacy associated with VV-14305 in participants with TED (as compared to Sham for Part 2) [Time frame: 52 Weeks]
- Efficacy associated with VV-14305 in participants with TED (as compared to Sham for Part 2) [Time frame: 52 Weeks]
- Efficacy associated with VV-14305 in participants with TED (as compared to Sham for Part 2) [Time frame: 52 Weeks]
- Efficacy associated with VV-14305 in participants with TED (as compared to Sham for Part 2) [Time frame: 52 Weeks]
- Effect of VV-14305 on quality of life (as compared to Sham for Part 2) [Time frame: 52 Weeks]
- Pharmacokinetics (PK) of VV-14305 transgene product [Time frame: 52 Weeks]
Eligibility criteria
Inclusion criteria
- Must be 18 to 80 years of age (inclusive) at Screening.
- Body Mass Index (BMI) of 19 to 34 kg/m2 (inclusive).
- Must be euthyroid (defined as normal thyroid-stimulating hormone) or have mild hyper- or hypothyroidism (being managed to bring them to a euthyroid state).
- Best Corrected Visual Acuity (BCVA) score of 20/60 or better at Screening with no history of deterioration noted in the 3 months prior to Screening.
- Must be willing and able to cease product use prior to VV-14305 (or sham) peribulbar injection if using non-steroidal anti-inflammatory drug (NSAIDs), medications or any herbal supplements, vitamins, or multivitamins with antiplatelet/anticoagulant properties.
- The study eye and the fellow eye must fall within the pre-defined degree of proptosis and clinical activity score (CAS) as measured at Screening.
- Participants must be diagnosed with TED prior to Screening and be diagnosed with Graves' disease and progressive moderate to severe TED at Screening.
Exclusion criteria
- History of serious ocular condition(s) other than TED, including but not limited to uveitis, dry age-related macular degeneration (AMD), and wet AMD; Other orbital or ophthalmic diseases, including inflammatory conditions, optic neuropathy, tumors, glaucoma with visual field defect or visual field loss, that in the opinion of the Investigator and/or Medical Monitor is clinically significant.
- Any medical, cognitive, or psychiatric condition that, in the opinion of the Investigator, could contraindicate the use of the investigational drug, make consistent study assessment and follow-up over the 12-month Post-Treatment Follow-up Period unlikely, or would make the participant an unsafe study candidate.
- Diagnosed with diabetes (HbA1c ≥6.5%).
- History of malignancy requiring chemotherapy and/or radiation in the 12 months prior to Screening, except for successfully treated nonmelanoma skin cancers (e.g., basal cell, squamous cell carcinomas), cervical intraepithelial neoplasia, and localized prostate cancer.
- Known allergy or condition that would contraindicate the use of required study medications.
- Any Screening assessment or laboratory value that, in the opinion of the Investigator and/or Medical Monitor, is clinically significant and renders the subject not suitable for study participation.
- Any vaccination or planned vaccination 30 days prior to dosing, 4 weeks post dosing or during period of immunosuppression.
- Participant requires or, in the opinion of the Investigator, is likely to require immediate surgical ophthalmological/orbital intervention or irradiation of either eye; Has had any prior surgery for TED including orbital decompression, strabismus surgery and any eyelid surgery on either eye.
- Prior participation in other gene therapy, investigational drug, biologic or device clinical trials within 30 days prior to Screening.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
New Zealand · 1 center
- Kriya Clinical Trial Site — Auckland
Identifiers
NCT: NCT07404111 · KRIYA-586-101